[1］Muller RH， Lherm C，Herbort J，et al.In vitro model for the degradation of alkylcyanoacrylate nanoparticles[J］.Biomaterials，1990，11：590. [2］Peracchia MT， Desmaele D， Couvreur P， et al. Synthesis of a novel MePEGcyanoarylate-hexadecylcyanoacrylate amiphiphilic copolymer for nanoparticle technology[J］.Macromolecules，1997， 30：846. [3］Ardis AE， Akron，Ohio， et al. Prepration of monomeric alkyl alpha-cyano-acrylates [P］.US Patent 2467927.1949-04-19. [4］Frederick B，Joyner F，Gary F， et al.Method of making a-cyanoacrylates[P］.US Patent 2721858.1955-10-25 [5］Brigger I， Chaminade P， Desmaele D， et al.Near infrared with principal component analysis as a novel analytical approach for nanoparticle technology[J］.Pharm Res，2000，17(9)：1124. [6］Stella B， Arpicco S， Peracchia MT， et al.Design of folic acid-conjugated nanoparticles for drug targeting[J］.J Pharm Sci，2000，89(11)：1452. [7］Li Y， Ogris M， Wagner E， et al. Nanoparticles bearing polyethyleneglycol-coupled transferrin as gene carriers：preparation and in vitro evaluation[J］.Int J Pharm，2003，59(1-2)：93. [8］?Li YP， Pei YY， Zhou ZH， et al.PEGylated polycyanoacrylate nanoparticles as tumor necrosis factor-alpha carriers[J］.J Controlled Release，2001，71(3)：287. [9］Peracchia MT， Vauthier C， Desmaele D， et al.PEGylated nanoparticles from a novel methoxypolyethylene glycol cyanoacrylate-hexadecyl cyanoacrylate amphililic copolymer[J］.Pharm Res，1998，15(4)：550. [10］Shen HW， Eisenberg A. Block length dependence of morphological phase diagrama of the terminary system of ps-b-pAA/vioxane/H2O[J］.Macromolecules，2000，33：2561. [11］Rainer HM， Catherine L， Jens H，et al.In vitro biocompatibility testing of polycyanoacrylate nanoparticles[J］.Biomaterials，1990，11：590. [12］Regina Z，Thomas K.Comparative in vitro biocompatibility testing of polycyanoacrylates and poly(D，L-lactide-co-glycolide)using different mouse fibroblast(L929) biocompatibility test models[J］.Eur J Pharm Biopharm，1997，44：149. [13］Peracchia MT， Fattal E， Desmaele D， et al. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting[J］.J Controlled Release，1999，60(1)：121. [14］Peracchia MT， Harnisch S， Pinto-Alphandary H， et al. Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles[J］.Biomaterials，1999，20(14)：1269. [15］Calvo P， Gouritin B， Brigger I，et al.PEGylated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases[J］.J Neurosic Methods，2001，111(2)：151. [16］Calvo P， Gouritin B， Chacun H， et al.Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery[J］.Pharm Res，2001，18(8)：1157. [17］Calvo P， Gouritin B， Villarroya H， et al.Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat[J］.Eur J Neuro Sci，2002，15(8)：1317. [18］Li YP， Pei YY， Zhou ZH， et al.Stealthpolycyanoacrylate nanoparticles as tumor necrosis factor-alpha carriers：pharmacokinetics and antitumor effects[J］.Biol Pharm Bull，2001，24(6)：662. [19］Li YP， Zhou ZH， Pei YY， et al.PEGylated polycyanoacrylate nanoparticles as salvicine carriers：synthesis，preparation and in vitro characterization[J］.Acta Pharmacol Sin，2001，22(7)：645.